NCT04427189

Brief Summary

SWEET-REGISTRY is a multi center, investigator initiated registry in patients with diabetes. SWEET' is an acronym derived from 'Better control in Pediatric and Adolescent diabeteS: Working to crEate CEnTers of Reference'. Having the vision of equal quality care for all children with diabetes the mission of SWEET is to harmonize care to optimize outcomes of children with diabetes worldwide. Initiated with support of the EU Public Health Program in 2008 the SWEET group has over 10 years of experience in creating and sustaining a high quality professional network based on agreed standards of care, criteria for certification, international guidelines and quality control. While originally focusing on the European region, SWEET is currently expanding and has received increasingly global attention, with centers across different continents including Asia, Africa, North and South-America. SWEET extracts wherever possible the data from existing data collection sources and following longitudinally unselected clinical populations of all pediatric diabetes patients as an ongoing measure of benchmarking and a quality control cycle as well as a resource for scientific studies and collaborative research. The SWEET registry was approved by the ethical committee of Hannover Medical School and is associated with the AUF DER BULT Diabetes Centre for Children and Adolescents, Hannover, Germany, which coordinates the SWEET collaboration. Each center has to meet specific entry criteria showing diabetes expertise and compliance with the International Society for Pediatric and Adolescent Diabetes (ISPAD) clinical practice guidelines. The local institutional review boards of the participating centers approved the pseudonymized data collection.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100,000

participants targeted

Target at P75+ for all trials

Timeline
29mo left

Started Apr 2008

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress89%
Apr 2008Sep 2028

Study Start

First participant enrolled

April 1, 2008

Completed
12.2 years until next milestone

First Submitted

Initial submission to the registry

May 28, 2020

Completed
14 days until next milestone

First Posted

Study publicly available on registry

June 11, 2020

Completed
7.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2028

Expected
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2028

Last Updated

October 15, 2024

Status Verified

October 1, 2024

Enrollment Period

20 years

First QC Date

May 28, 2020

Last Update Submit

October 9, 2024

Conditions

Keywords

Pediatric

Outcome Measures

Primary Outcomes (1)

  • Change of HbA1c level

    assessment of the metabolic situation based on the level of HbA1c

    through study completion, an average of 1 year, up to 5 years

Secondary Outcomes (3)

  • hypoglycemia rate

    through study completion, an average of 1 year, up to 5 years

  • Time in Range

    through study completion, an average of 1 year, up to 5 years

  • DKA rate

    through study completion, an average of 1 year, up to 5 years

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients from Diabetes centres worldwide diagnosed with Diabetes mellitus

You may qualify if:

  • Diabetes mellitus (as diagnosed clinically)
  • Males and females of all Ages, but with a focus on pediatric care
  • Provision of informed consent from participant and all legal representatives prior to any study specific procedures

You may not qualify if:

  • no diabetes
  • no consent,
  • Patient who, in the judgment of the Investigator, is found to be unlikely to comply with the protocol, or has any severe concurrent medical or psychological condition that may affect the interpretation of efficacy or safety data

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Kinderkrankenhaus auf der Bult

Hanover, Low Saxony, 30173, Germany

RECRUITING

Related Publications (4)

  • Chobot A, Eckert AJ, Biester T, Corathers S, Covinhas A, de Beaufort C, Imane Z, Kim J, Malatynska A, Moravej H, Pokhrel S, Skinner T, Study Group S. Psychological Care for Children and Adolescents with Diabetes and Patient Outcomes: Results from the International Pediatric Registry SWEET. Pediatr Diabetes. 2023 Jun 2;2023:8578231. doi: 10.1155/2023/8578231. eCollection 2023.

  • Limbert C, Lanzinger S, deBeaufort C, Iotova V, Pelicand J, Prieto M, Schiaffini R, Sumnik Z, Pacaud D; SWEET Study Group. Diabetes-related antibody-testing is a valuable screening tool for identifying monogenic diabetes - A survey from the worldwide SWEET registry. Diabetes Res Clin Pract. 2022 Oct;192:110110. doi: 10.1016/j.diabres.2022.110110. Epub 2022 Sep 30.

  • Danne T, Lanzinger S, de Bock M, Rhodes ET, Alonso GT, Barat P, Elhenawy Y, Kershaw M, Saboo B, Scharf Pinto M, Chobot A, Dovc K. A Worldwide Perspective on COVID-19 and Diabetes Management in 22,820 Children from the SWEET Project: Diabetic Ketoacidosis Rates Increase and Glycemic Control Is Maintained. Diabetes Technol Ther. 2021 Sep;23(9):632-641. doi: 10.1089/dia.2021.0110. Epub 2021 Aug 18.

  • Gerhardsson P, Schwandt A, Witsch M, Kordonouri O, Svensson J, Forsander G, Battelino T, Veeze H, Danne T. The SWEET Project 10-Year Benchmarking in 19 Countries Worldwide Is Associated with Improved HbA1c and Increased Use of Diabetes Technology in Youth with Type 1 Diabetes. Diabetes Technol Ther. 2021 Jul;23(7):491-499. doi: 10.1089/dia.2020.0618. Epub 2021 Feb 26.

MeSH Terms

Conditions

Diabetes Mellitus, Type 1

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesAutoimmune DiseasesImmune System Diseases

Study Officials

  • Thomas Danne, MD

    Kinderkrankenhaus auf der Bult

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Olga Prof. Kordonouri, MD

CONTACT

Bärbel Dr. Aschemeier-Fuchs, PH

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
20 Years
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prof. Dr.

Study Record Dates

First Submitted

May 28, 2020

First Posted

June 11, 2020

Study Start

April 1, 2008

Primary Completion (Estimated)

April 1, 2028

Study Completion (Estimated)

September 1, 2028

Last Updated

October 15, 2024

Record last verified: 2024-10

Locations